Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.» Read More
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.
Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.
NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.
U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.
July 1- Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.
Some of the names on the move ahead of the open.
NEW YORK, June 25- U.S. stock investors ignored weak economic data and pushed equities higher on Wednesday, as drugmakers' shares rose and a Supreme Court ruling lifted major broadcaster stocks, while German bond yields hit the year's low on safe-haven bids.
*Monsanto rallies on outlook and stock-repurchase plans. *CBS shares jump after Supreme Court ruling. Shares of CBS jumped 6.2 percent to $62.48 after the U.S. Supreme Court ruled that online TV startup Aereo Inc violates copyright law by using tiny antennas to provide subscribers with broadcast network content via the Internet.
U.S. stocks rose on Wednesday after mixed economic reports.
*Monsanto rallies after results; General Mills lower. *Medical Action almost doubles, Owens& Minor to buy.
Take a look at some of Wednesday's midday movers.
*Monsanto rallies after results, General Mills lower. NEW YORK, June 25- U.S. stocks edged higher on Wednesday as investors continued to find value in equities over other asset classes despite the latest economic data coming in below expectations.
*Investors watching Iraq violence; crude prices rise. *Monsanto rallies after results, General Mills lower. NEW YORK, June 25- U.S. stock index futures pointed to a lower open on Wednesday as the latest economic data came in below expectations, giving investors further reasons to take profits amid ongoing tension in Iraq.
*Investors watching Iraq tension, crude oil rises early. Durable goods orders, also due at 8:30 a.m., are seen as flat in May, while a June read on service sector business activity from financial data firm Markit is seen as essentially unchanged from May.